A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants
Condition: Healthy Volunteers
Intervention: LY2944876; Placebo
Intervention description: Administered SC; Administered SC
Phase: Phase 1
Study type: Interventional
Primary purpose: Basic Science
Allocation: Randomized
Intervention model: Sequential Assignment
Masking: Double (Participant, Investigator)
Enrollment: 48.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      LY2944876 is an investigative drug for the treatment of Type 2 Diabetes Mellitus. Part A of
      the study will assess the safety and tolerability of single doses of LY2944876 in Japanese
      participants. Participation is expected to last up to about 7 weeks, not including screening.

      Part B of the study will investigate the safety and tolerability of multiple doses of
      LY2944876 in non Japanese participants. Participation is expected to last up to about 8
      weeks, not including screening.

      All doses will be administered as injections into the fatty layer just beneath the skin.

      Screening is required within 28 days prior to the start of the study. All participants will
      attend a post study safety assessment approximately 6 weeks after their final dose.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Healthy males or female participants

          -  Are first generation Japanese participants (Part A) or non-Japanese participants (Part
             B)

          -  Have a body mass index (BMI) of 18.5 to 30 kilogram per meter square (kg/m^2),
             inclusive, for Part A and a BMI of 25 to 40 kg/m^2, inclusive, for Part B at screening

          -  Have normal blood pressure and heart rate (after approximately 5 minutes supine and
             approximately 2 minutes standing) as determined by the investigator at screening

        Exclusion Criteria:

          -  Have known allergies to LY2944876, related compounds or any components of the
             formulation, or history of significant atopy

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) at screening and/or
             baseline that, in the opinion of the investigator, increases the risks associated with
             participating in the study

          -  Have significant history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  Have a history of acute or chronic pancreatitis or elevation in serum lipase and/or
             amylase greater than 2 times the upper limit of normal (ULN) at screening and/or
             baseline

          -  Have known or ongoing psychiatric disorders considered clinically significant in the
             opinion of the investigator

          -  Have undergone any form of bariatric surgery

          -  Have fasting blood glucose levels greater than or equal to (≥) 7 millimoles per liter
             (mmol/L) [≥126 milligrams per deciliter (mg/dL)] at screening

          -  Have fasting triglycerides levels ≥300 mg/dL (3.4 mmol/L) at screening

          -  Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis,
             or an alanine transaminase (ALT) or aspartate aminotransferase (AST) levels greater
             than (>) 2.5 times the ULN at screening and/or baseline

          -  Have used or intend to use medications that promote weight loss, within 3 months prior
             to screening, for the duration of the study